MADISON, Wis., Dec. 1, 2015 /PRNewswire/ -- Propeller
Health, provider of an FDA-cleared digital health solution for
improving outcomes in asthma and chronic obstructive pulmonary
disease (COPD), today announced a development agreement and R&D
collaboration with GSK for its Ellipta® inhaler,
the pharmaceutical company's innovative, patented, dry powder
inhaler.
Under the terms of this non-exclusive agreement, the first
between the two companies, Propeller Health will develop and
manufacture a custom sensor for the Ellipta inhaler for use in
certain GSK clinical studies in asthma and COPD.
In the studies, the sensor will automatically collect and record
data on the inhaler's usage (i.e. date and time of each use),
wirelessly transmitting the information to a central data
repository for analysis by GSK's clinical researchers. The sensor
technology will be used to provide greater insights into adherence
patterns across patient populations and may allow for more precise
correlation of adherence with safety, efficacy and economic
outcomes.
GSK retains an option to negotiate exclusive commercialization
rights to the sensor for use with its marketed portfolio of
respiratory medicines administered using the Ellipta
inhaler.
"We are pleased to announce a collaboration with GSK, a global
leader in the treatment of respiratory disease. Together we aim to
combine our expertise to empower patients and positively impact
care," said David Van Sickle, CEO
and co-founder of Propeller.
Dave Allen, Senior Vice President
of Respiratory R&D at GSK, said, "We continue to find new and
better ways to conduct clinical trials by exploring novel patient
centered outcomes through strategic collaborations. Using
innovative sensor technology to improve the quality of adherence
data collected during our studies will advance our understanding of
disease and inform our decision-making in the development of new
medicines."
The Propeller platform has been used by patients in over 35
commercial programs across the United
States, including major healthcare systems, payers,
employers and other commercial partners. It is compatible with the
majority of commonly used asthma and COPD inhaler devices including
controller and reliever metered dose inhalers (MDIs), and other
inhaler devices (dry powder inhaler (DPI) and soft mist inhaler
(SMI)).
Propeller creates a custom view of each patient, allowing them
and their physicians to better understand the impact and management
of their disease in daily life. To date, the Propeller platform has
received FDA 510(k) class II clearance to measure and improve
medication adherence, help predict exacerbations, and help reduce
the frequency of symptoms and exacerbations in asthma and COPD.
GSK is a global leader in respiratory medicine, providing a
portfolio of licensed medicines for asthma and chronic obstructive
pulmonary disease (COPD). The Ellipta inhaler is a platform inhaler
device that is being used by GSK in the development of a range of
innovative medicines across its clinical development portfolio for
respiratory diseases.
Development and marketing of the Propeller platform in
association with medicines for asthma and COPD using the
Diskus® dry powder inhaler is the sole
responsibility of Propeller Health and is not the subject of
this or any other collaboration with GSK.
About Propeller Health
Founded in 2010, Propeller is provider of an FDA-cleared digital
health platform that helps reduce the cost of care while delivering
better quality of life for individuals with chronic respiratory
disease. Backed by Safeguard Scientifics (NYSE: SFE), The
Social+Capital Partnership, California HealthCare Foundation, and
other investors. Propeller Health has been used by patients with
asthma or COPD in over 35 commercial programs across the US,
including major healthcare systems, payers, employers and other
commercial partners. Company recognition includes TEDMED Innovation
Showcase, White House Champion of Change, and Bluetooth
Breakthrough Product awards. Visit
http://propellerhealth.com/contact/ to request more information
about purchasing the Propeller system.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/propeller-health-announces-development-agreement-and-rd-collaboration-with-gsk-to-develop-a-digital-sensor-for-the-ellipta-inhaler-300185855.html
SOURCE Propeller Health